01—Abstract
Summary
Summary of the 8-K filed June 1, 2026. Cited figures are marked; the original filing is the authoritative source.
On May 28, 2026, International Flavors & Fragrances Inc. (IFF) entered into a Transaction Agreement with Foxtrot US Bidco, Inc. and Foxtrot Midco LP, affiliates of CVC Capital Partners, to sell its Food Ingredients business.
The transaction values the business at approximately $4.3 billiona. IFF expects net cash proceeds of approximately $3.8 billion at closing, subject to customary adjustments, and a minority equity interest in the future company valued at approximately $200 million, expected to represent an approximate 9.9% stake at closing. The press release furnished with the filing states the sale is a significant step in IFF's portfolio transformation, concentrating the company on Taste, Scent, and Health & Biosciences.
The Food Ingredients business generated nearly $3.1 billionb in annual sales and approximately $430 million of EBITDA in 2025, and the transaction values it at roughly 10x enterprise value-to-EBITDA. IFF expects the transaction to be dilutive to adjusted EPS in the first 12 months after closing, prior to benefits from capital deployment and actions to address stranded overhead costs. The company reiterated its full-year 2026 guidance, with sales of $10.5 billion to $10.8 billion and adjusted operating EBITDA of $2.05 billion to $2.15 billion.
Closing is subject to customary conditions, including Hart-Scott-Rodino and other regulatory approvals, and is expected by the end of the second quarter of 2027. The agreement may be terminated if the transaction is not consummated by May 28, 2027, or upon uncured breaches that cause a closing condition to fail. IFF intends to use proceeds for debt reduction, targeted share repurchases, and reinvestment in the core portfolio.
02—Key points
Key Highlights
- Sale of Food Ingredients business to affiliates of CVC Capital Partners at a transaction value of approximately $4.3 billion
- Expected net cash proceeds of approximately $3.8 billion at closing, subject to customary adjustments
- IFF to retain a minority equity interest valued at approximately $200 million, expected to represent an approximate 9.9% stake at closing, and a board seat
- Food Ingredients generated nearly $3.1 billion in annual sales and approximately $430 million of EBITDA in 2025
- Transaction expected to be dilutive to adjusted EPS in the first 12 months after closing, before capital deployment benefits and stranded overhead actions
- Full-year 2026 guidance reiterated: sales of $10.5 billion to $10.8 billion and adjusted operating EBITDA of $2.05 billion to $2.15 billion
- Expected closing by end of second quarter 2027; outside termination date of May 28, 2027
03—Questions
Frequently Asked Questions
How much cash will IFF receive from the sale?
IFF expects to receive net cash proceeds of approximately $3.8 billion at closing, reflecting the rolled-over equity, customary purchase price adjustments, costs to stand up and carve out the business, and taxes.
What stake will IFF keep in the business after the sale?
IFF will retain a minority equity interest valued at approximately $200 million, expected to represent an approximate 9.9% stake at closing, and will hold a board seat in the new company.
What will IFF do with the proceeds?
The company intends to prioritize debt reduction, targeted share repurchases as authorized by the Board, and reinvestment in high-return opportunities across the core portfolio.
What conditions must be met for the transaction to close?
Closing requires customary mutual conditions, including the absence of certain injunctions, expiration or termination of Hart-Scott-Rodino waiting periods, and certain non-U.S. approvals, along with the accuracy of representations and performance of covenants. The transaction is expected to close by the end of the second quarter of 2027.
How will the sale affect IFF's earnings in the near term?
IFF expects the transaction to be dilutive to adjusted EPS in the first 12 months following closing, before benefits from capital deployment and any actions to address stranded overhead costs. The company believes the strategic and financial benefits outweigh this near-term impact.
04—Continue